G1 Therapeutics: trilaciclib shows benefits for lung cancer patients

By Jenni Spinner contact

- Last updated on GMT

(Image: Getty/mr suphachai praserdumrongchai)
(Image: Getty/mr suphachai praserdumrongchai)

Related tags: Lung cancer, Clinical trials, Oncology, Research and development

The company will present data from recent Phase 2 trials of the investigational drug at the upcoming ASCO20 virtual conference on May 29.

G1 Therapeutics, a clinical-stage oncology firm, announced the upcoming presentation of data across three randomized, double-blind, placebo-controlled Phase 2 trials of the investigational drug trilaclib. The company will unveil the data May 29 at the ASCO20 (American Society of Clinical Oncology) Virtual Scientific Program.

According to the company, trilaciclib administered to patients prior to chemotherapy showed significantly reduced rates of myelosuppression and the need for related supportive care interventions compared with patients receiving chemotherapy treatment alone.

Raj Malik, chief medical officer and senior vice president of R&D for the company, said the data indicates trilaciclib shows promise to improve outcomes for chemotherapy patients.

Patients with chemotherapy-induced myelosuppression are especially vulnerable and often require multiple rescue interventions that are burdensome to both the patient and the healthcare system​,” he said. “Trilaciclib has the potential to be the first proactively administered myelopreservation therapy that can make chemotherapy safer and improve the patient experience.​”

Myelosuppression is the result of damage to bone marrow cells, and is one of the most common side effects of chemotherapy. The condition often calls for rescue interventions (like growth factors and blood or platelet transfusions) and can lead to chemotherapy dose delays and reductions.

Additionally, resulting immune cell damage may decrease the ability of the immune system to fight the cancer, or infections. Trilaciclib is an investigational therapy intended to preserve bone marrow and immune system function during chemotherapy and improve patient outcomes.

G1 Therapeutics reports it intends to complete an NDA submission for trilaciclib for myelopreservation in small-cell lung cancer in the second quarter of the year. The drug has been assigned Breakthrough Therapy Designation by the US Food and Drug Administration (FDA).

The abstracts G1 Therapeutics will be presenting during the ASCO20 event are:

  • “Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer”
  • “Real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey of patients with cancer”
  • “Title: Real-world burden of myelosuppression in patients with small cell lung cancer: retrospective, longitudinal data analysis”

Additional details are available at the event website, meetings.asco.org/am/virtual-format

Related news

Related products

show more

Facilities: Lexington, KY USA

Facilities: Lexington, KY USA

Piramal Pharma Solutions | 23-Aug-2021 | Insight Guide

The Piramal Pharma Solutions facility in Lexington, KY USA is a fully integrated site which offers analytical, formulation development, and manufacturing...

Facilities: Sellersville, PA USA

Facilities: Sellersville, PA USA

Piramal Pharma Solutions | 23-Aug-2021 | Insight Guide

The Piramal Pharma Solutions facility in Sellersville, PA USA is a fully integrated site that offers product and process development, clinical supply and...

Related suppliers

Follow us

Products

View more

Webinars